Update of acute kidney injury: Intensive care nephrology

Hippokratia

Volumn 15, Issue SUPPL. 1, 2011, Pages 53-68

  Tsagalis, G ^a  

^a Renal Unit   (Greece)

Author keywords

Intensive care nephrology; N galactosamine; Renal replacement therapy (RRT); Sequential organ failure assessment

Indexed keywords

ACETYLCYSTEINE; ACICLOVIR; ADEFOVIR; AMINOPHYLLINE; ATRIAL NATRIURETIC FACTOR; CIDOFOVIR; CLONIDINE; COLISTIN; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ERYTHROPOIETIN; FUROSEMIDE; HYDROCORTISONE; INDINAVIR; IODINATED CONTRAST MEDIUM; LAMIVUDINE; MANNITOL; NESIRITIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THEOPHYLLINE; UNINDEXED DRUG; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ANEMIA; ARTIFICIAL VENTILATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTRAST INDUCED NEPHROPATHY; CRITICAL ILLNESS; CRYSTALLURIA; DIALYSIS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; HEART ARRHYTHMIA; HEART SURGERY; HUMAN; HYPOTHYROIDISM; INTENSIVE CARE; INTERSTITIAL NEPHRITIS; INTESTINE BLOOD FLOW; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; LUNG EDEMA; MORBIDITY; NEPHROLITHIASIS; NEPHROLOGIST; NEPHROSIS; NONHUMAN; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; PROGNOSIS; REVIEW; SEPTIC SHOCK; SIDE EFFECT; T LYMPHOCYTE;

EID: 79952392482     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol 2004; 15: 1597-1605.
2. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-Definition, outcome measures, animal models, fluid therapy and information technology needs:The Second International Consensus Conference f the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212
3. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: Physiological principles. Intensive Care Med 2004; 30: 33-37.
4. Lamiere N, Hoste E. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care 2004; 10: 468-475
5. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by cystatin C. Kidney Int 2004; 66: 1115-1122.
6. Ricki H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, et al. Time course of serial cystatin levels in comparison with serum creatinine after application of radiocontrast media. Clinical Nephrology 2004; 61: 98-102.
7. Han Wk, Bonventre JV. Biologic markers for early detection of acute kidney injury. Curr Opin Crit Care 2004; 10: 476-482.
8. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286: 552-563.
9. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-2543.
10. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
11. Parikh CR, Jani A, Melnikov VY, Faubel S, Eldestein CL. Urinary Interleucin 18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43: 405-414.
12. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute renal injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005; 16: 3046-3052.
13. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, et al. Program to improve Care in Acute Renal Disease:Spectrum of acute renal failure in the intensve care unit:The PICARD experience. Kidney Int 2004; 66: 1613-1621.
14. Chertow GM, Pascual MT, Soroko S, Svage BR, Himmelfarb J, Ikizler TA, et al. PICARD: Reasons for non enrollment in a cohort study of ARF:The Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. Am J Kidney Dis 2003; 42: 507-512.
15. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Beginning and ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute Renal Failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294: 813-818.
16. Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary center from 1991 to 2001. Am J Kidney Dis 2005; 45: 96-101.
17. Sesso R, Roque A, Vicioso B, Stella S. Prognosis of ARF in hospitalized elderly patients. Am J Kidney Dis 2004; 44: 410-419.
18. Zhou H, Hewitt S, Yen P. Acute kidney disease biomarkers- Needs, Present Status and future promise. Editorial In Nephrology Self-assessment program 2006; 5: 63-72.
19. st edition 2005.
20. Ferreira FL, Bota DP, Bross A, Milot C, Vincent JL. Serial evaluations of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754-1758.
21. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, et al. Preoperative Renal Riske stratification. Circulation 1997; 95: 878-884.
22. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al. Intensity of renal support in critically ill patients with acute kidney injury. NEJM 2008; 359: 7-20.
23. Palevsky PM, O'Connor TZ, Chertow GM, Crowley ST, Zhang JH, Kellum JA; Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. Crit Care. 2009; 13(4): 310.
24. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute Renal Failure in intensive care units-causes, outcome and prognostic factors on hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192-198.
25. Chen YC, Hsu HH, Kao KC, Fang JT, Huang CC. Outcomes and APACHE II predictions for5 critically ill patients with acute renal failure requiring dialysis. Ren Failure 2001; 23: 61-70.
26. De Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Medicine 2000; 26: 915-921.
27. Zager RA: Endotoxemia, renal hypoperfusion and fever:Interactve risk factors for aminoglycoside and sepsis-induced acute renal failure. Am J Kidney Dis 1992; 20: 223-230.
28. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210.
29. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis and therapy. J Clin Invest 2004; 114: 5-14.
30. Lamiere N, Vanholder R. Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 2001; 12(Suppl 1): S20-S32.
31. Lamiere N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417-430.
32. Brezis M, Rosen S. Hypoxia of the renal medulla-Its implications for disease. N Engl J Med 1995; 332: 647-655.
33. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363
34. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney 2005; 67: 524-528.
35. Al Awqati Q, Oliver JA. Stem cells in the kidney. Kidney Int 2002; 61: 387-395.
36. Togel F, Hu Z, Weiss K. Adminestered mesenchymal stem cells protect against acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: 31-42.
37. Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, et al. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow derived stem cells. J Clin Invest 2005; 115: 1743-1755.
38. Stokman G, Leemans JC, Claessen N. J Am Soc Nephrol 2005; 16: 1684-1692.
39. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93: 1515-1519.
40. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiology 2004; 44: 1780-1785.
41. Merten GJ, Buregess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328-2334.
42. Pannu N, Manns B, Lee H. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004; 65: 1366-1374.
43. Ochoa A, Pellizon G, Addala S. Abbreviated dosing of N-acetylcysteine prevents contrast induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 2004; 17: 159-165.
44. Ix JH, McCullooch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: A meta-analysis. Nephrol Dial Transplant 2004; 19: 2747-2753.
45. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast- induced nephropathy. A systematic review and meta-analysis. Arch Intern Med 2005; 165: 1087-1093.
46. Mangano CM, Diamondstone LS, Ramsay JG. Renal dysfunction after myocardial revascularization: Risk factors, adverse outcomes, and hospital resource utilization. Ann Intern Med 1998;128: 194-203.
47. Tuutle KR, Worrall NK, Dahlstrom LR, Nandagopal R, Kausz AT, Davis CL. Predictors of ARF after cardiac surgery procedures. Am J Kidney Dis 2003; 41: 76-83.
48. Nigwerker SU, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a metaanalysis of randomized and observational studies. Am J Kidney Dis 2009; 54; 413-423.
49. Schwann NM, Horrow JC, Strong MD 3rd, Chamchad D, Guerraty A, Wechsler AS. Does off-pump bypass reduce the incidence of clinically evident renal dysfunction after multivessel myocardial revascularization? Anesth Analg 2004; 99:959-964.
50. Mackay JH, Feerick AE, Woodson LC, Lin CY, Deyo DJ, Uchida T, et al. Increasing organ blood flow during cardiopulmonary bypass in pigs: Comparison of dopamine and perfusion pressure. Crit Care Med 1995; 23: 1090-1098.
51. O'Dwyer C, Woodson LC, Conroy BP. Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 1997; 63: 728-735
52. Urzua J, Troncoso S, Bugedo G, Canessa R, Muoz H, Lema G, et al. Renal function and cardiopulmonary bypass: Effects of perfusion pressure. J Cardiothoracic Vasc Anesth 1992; 6: 299-303.
53. Andersson LG, Jeppsson A, Bratteby LE, Ekroth R, Joachimsson PO, van der Linden J, et al. Renal function after cardiopulmonary bypass: Influence of pump flow and systemic blood pressure. Eur J Cardiothoracic Surg 1994; 8: 597-602.
54. Kulka PJ, Tryba M, Zenz M. Preoperative alpha-2 adrenergic receptor agonists prevent the deterioration of renal function after cardiac surgery: Results of a randomised, controlled trial. Crit Care Med 1996; 24: 947-952.
55. Myles PS, Hunt Jo, Holdgaard Ho, McRae R, Buckland MR, Moloney J, et al. Clonidine and cardiac surgery: Haemodynamic and metabolic effects, myocardial ischemia nad surgery. Anaesth Intensuve Care 1999; 27: 137-147.
56. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide after cardiac surgery. J Am Soc Neph 2000; 11: 97-104.
57. Sward K, Vaksson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuertic peptide in ischemic acute renal failure. A randomised placebo controlled trial. Crit Care Med 2004; 32: 1310-1315.
58. Sward K, Valsson F, Sellgren J, Ricksten SE. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and oxygen cinsumption in humans. Intensive Care Med 2005; 31: 79-85.
59. Argalious M, Motta P, Khandwala F. "Renal dose" dopamine is associated with the risk of new onset atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33: 1327-1332.
60. Halpenny M, Rushe C, Breen P, Cunningham AJ, Boucher- Hayes D, Shorten GD. The effects of fenoldopam on renal function on patients undergoing elective aortic surgery. Eur J Anesthes 2002; 19: 32-39.
61. Bove T, Landoni G, Calabro MG, Aletti G, Marino G, Cerchierini E, et al. Renoprotective action of fenoldopam in high risk patients undergoing cardiac surgery. A prospective, double blind randomised clinical trial. Circulation 2005; 111: 3230-3235.
62. Daugas E, Rougier J-P, Hill G. HAART-related nephropathies in HIV infected patients. Kidney Int 2005; 67: 393-403.
63. Unnikrishnan D, Satish B. Exertion-induced rhabdomyolysis in a patient on statin therapy. Nephrol Dial Tranplant 2005; 20: 244.
64. Fernandez WG, Hung O, Bruno GR, Galea S, Chiang WK. Factors predictive of acute renal failure and need for hemodialysis among ED patients with rabdomyolysis. Am J Emerg Med 2005; 23: 1-7.
65. Sharp LS, Rozycki GS, Feliciano DV. Rhabdomyolysis and secondary renal failure in critically ill surgical patients. Am J Surg 2004; 188: 801-806.
66. Gunal AI, Celiker H, Dogukan A, Ozalp G, Kirciman E, Simsekli H, et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004; 15: 1862-1867.
67. Brown CV, Rhee P, Chan L, Evans K, Demetriades D, Velmahos GC. Preventing renal failure in patients with rhabdomyolysis: Do bicarbonate and mannitiol make a difference? J Trauma 2004; 56: 1191-1196.
68. Huerta C, Castellague J, Varas Lorenzo, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of acute renal failure in the general population. Am J Kidney Dis 2005; 45: 531-539.
69. Braden GL, O'Shea MH, Mulhern JG, Germain MJ. Acute renal failure and hyperkalemia associated with cycloxygenase-2 inhbitors. Nephrol Dial Transplat 2004; 19: 1149-1153.
70. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45: 804-817.
71. Casserly B, O'Mahony E, Timm EG, Haqqie S, Eisele G, Urizar R. Propofol infusion syndrome:An unusual cause of renal failure. Am J Kidney Dis 2004; 44: 98-101.
72. Daram SR, Gogia S, Bastani B. Colistin-associated acute renal failure revisited. South Med J 2005; 98: 257-258.
73. Normile D. Researchers tie deadly SARS virus to bats. Science 2005; 309: 2154-2155.
74. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus associated severe acute respiratory syndrome. Kidney Int 2005; 80: 703-704.
75. Karthik S, Pjadke KD. Snakebite-induced acute renal failure. A case report and review of the literature. Pediatr Nephrol 2004; 19:1053-1054.
76. Schneemann M, Cathomas R, Laidlaw ST, El Nahas AM, Theakston RD, Warrell DA. Life threatening envenoming by the Saharan horned viper (Ceraste ceraste) causing microangiopathic haemolysis, coagulopathy and acute renal failure: Clinical cases and review QJM 2004; 97: 717-727.
77. Pinho FM, Zanetta DM, Burdmann EA. Acute renal failure after Croralus durissus snakebite: A prospective survey on 100 patients. Kidney Int 2005; 67: 659-667.
78. Ozuecelik DN, Karcioglu O, Topacoglu H, Fowler JR. Toxicity following unintentional DDT ingestion. J Toxicom Clin Toxicol 2004; 42:299-302.
79. Markowitz GS, Nasr SH, Klein P, et al. Renal failure and acute nepjrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35: 675-684.
80. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative:An unrecognised cause of chronic renal failure. J Am Soc Nephrol 2005; 16: 3389-3396.
81. PT. Use of dopaminergic agents for renoprotection in the ICU: Year book of Intensive Care And Emergency Mdeicine, Springer-Verlag 2003; 637-648.
82. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low dose dopamine in patients with early renal dysfunction: A placebo controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-2143.
83. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL. High dose furosemide in Acute Renal Failure Study Group: High dose furosemide for established ARF: A prospective, randomised, doble-blind, placebo-controlled, multicenter tria. Am J Kid Dis 2004; 44: 402-409.
84. Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52: 3886-3894.
85. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short term risk of death after treatment with nesiritde for decompensated heart failure. A pooled analysis of randomised controlled trials. JAMA 2005; 293: 1900-1905.
86. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
87. Palevsky PM. Acute Renal Failure. NephSAP 2003; 2: 41-85.
88. Palevsky PM. Acute Renal Failure. NephSAP 2004; 3: 245-284.
89. Elahi MM, Lim MY, Joseph RN, Dhannapuneni RR, Spyt TJ. Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure. Eur J Cardiothorac Surg 2004; 26: 1027-1031.
90. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, et al. NHLBI Acute Respiratory Distress Syndrome Clinical Trials Network: Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33: 1-6.
91. Cheng IW, Eisner MD, Thompson BT, Ware LB, Matthay MA. Acute Respiratory Distress Syndrome Network: Acute effects of tidal volume strategy on hemodynamics, fluid balance, and sedation in acute lung injury. Crit Care Med 2005; 33:63-70.
92. Hough CL, Kallet RH, Ranieri VM, Rubenfeld GD, Luce JM, Hudson LD. Intrinsic positive end-expiratory pressure in Acute Respiratory Distress Syndroem (ARDS) Network subjects. Crit Care Med 2005; 33: 766-771.
93. Ranieri VM, Suter P, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomised controlled trial. JAMA 199; 282: 54-61.
94. Scweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily interruption of sedative infusions and complications of critical illness on mechanically ventilated patients. Crit Care Med 2004; 32: 1271-1276.
95. Kress JP, Gehlbach BK, Lacy M. The long term psychological effects of daily sedative interruption on critically ill patients. Am J Respir Crit Care Med 2003; 168: 1457-1461.
96. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators. A Comparison Of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-2256.
97. Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, Vaughn WK, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: Effect on patient outcome. Transfusion 1999; 39: 1070-1077.
98. Corwin HI, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomised, double-blind, placebocontrolled trial. Crit Care Med 1999; 27: 2346-2350.
99. Corwin HI, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. EPO Critical Care Trials Group: Efficacy of recombinant human erythropoietin in critically ill patients. JAMA 2002; 288: 2827-2835.
100. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Emgl J Med 2001; 345: 588-595.
101. Schmid PG, Abboud FM, Wendling MG, Ramberg ES, Mark AL, Heistad DD, et al. Regional vascular effects of vassopressin: Plasma levels and circulatory responses. Am J Physiol 1974; 227: 998-1004.
102. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short term vasopressin infusion during severe septic shock. Crit Care Med 2001; 29: 487-493.
103. Tsuneyoshi I, Yamada H, Kakihana Y. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29: 487-493.
104. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock:Systemic, renaland splachnic hemodynamic and oxygen transport effects. J Appl Physiol 2003; 95: 803-809.
105. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomised, double-blind, single center study. Crit Care Med 1999; 27: 723-732.
106. Annane D, Sebille V, Charpentier C, Bollaert PE, Franois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality of patients with septic shock, JAMA 2002; 288: 862-871.
107. Loriaux L. Glucocorticoid therapy in the intensive care unit. N Engl J Med 2004; 350: 1601-1602.